BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22030099)

  • 1. Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies.
    Zhao Y; Ma Y; Fang Y; Liu L; Wu S; Fu D; Wang X
    Mol Genet Metab; 2012 Jan; 105(1):141-8. PubMed ID: 22030099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk.
    Wang M; Lang X; Cui S; Zou L; Cao J; Wang S; Wu X
    DNA Cell Biol; 2012 Jun; 31(6):975-82. PubMed ID: 22320866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
    Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
    Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?
    Mackness M; Mackness B
    Free Radic Biol Med; 2004 Nov; 37(9):1317-23. PubMed ID: 15454272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women.
    van Himbergen TM; van der Schouw YT; Voorbij HA; van Tits LJ; Stalenhoef AF; Peeters PH; Roest M
    Atherosclerosis; 2008 Aug; 199(2):408-14. PubMed ID: 18164014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease.
    Mackness B; Hine D; McElduff P; Mackness M
    Atherosclerosis; 2006 Jun; 186(2):396-401. PubMed ID: 16140307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study.
    Mackness B; Durrington P; McElduff P; Yarnell J; Azam N; Watt M; Mackness M
    Circulation; 2003 Jun; 107(22):2775-9. PubMed ID: 12756158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease].
    Gamboa R; Regalado JC; Huesca-Gómez C; Posadas-Romero C; Verdejo Paris J; Vargas-Alarcón G; Pérez-Méndez O
    Arch Cardiol Mex; 2008; 78(4):360-8. PubMed ID: 19205543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients.
    Kotur-Stevuljevic J; Spasic S; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Stefanovic A; Vujovic A; Memon L; Kalimanovska-Ostric D
    Clin Biochem; 2008 Sep; 41(13):1067-73. PubMed ID: 18634772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies.
    Wang M; Lang X; Zou L; Huang S; Xu Z
    Atherosclerosis; 2011 Feb; 214(2):377-85. PubMed ID: 21146823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status.
    Domagała TB; Łacinski M; Trzeciak WH; Mackness B; Mackness MI; Jakubowski H
    Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(5):4-10. PubMed ID: 17543199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of the association between paraoxonase1 55 Met/Leu, paraoxonase2 148 Ala/Gly and manganese superoxide dismutase (MnSOD) 9 Ala/Val genetic polymorphisms and coronary heart disease].
    Chi DS; Ling WH; Ma J; Xia M; Hou MJ; Wang Q; Zhu HL; Tang ZH; Yu XP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Sep; 27(9):808-13. PubMed ID: 17299970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
    Gugliucci A
    Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
    Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
    Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs.
    Kasprzak M; Iskra M; Majewski W; Wielkoszyński T
    Clin Biochem; 2009 Jan; 42(1-2):50-6. PubMed ID: 18976644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraoxonase and coronary heart disease.
    Mackness MI; Mackness B; Durrington PN
    Atheroscler Suppl; 2002 Dec; 3(4):49-55. PubMed ID: 12573363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.
    Mackness MI; Durrington PN; Mackness B
    Am J Cardiovasc Drugs; 2004; 4(4):211-7. PubMed ID: 15285696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpectedly higher diazoxon hydrolysis by serum paraoxonase-1 in coronary heart disease.
    Mackness B; Mackness M
    Clin Biochem; 2019 Mar; 65():21-23. PubMed ID: 30659791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.
    Kotani K; Watanabe J; Miura K; Gugliucci A
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33923656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population.
    Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD
    Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.